Rüediger Liersch

2.7k total citations
33 papers, 942 citations indexed

About

Rüediger Liersch is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Rüediger Liersch has authored 33 papers receiving a total of 942 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Cancer Research and 10 papers in Molecular Biology. Recurrent topics in Rüediger Liersch's work include Lymphatic System and Diseases (6 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Rüediger Liersch is often cited by papers focused on Lymphatic System and Diseases (6 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Rüediger Liersch collaborates with scholars based in Germany, United States and United Kingdom. Rüediger Liersch's co-authors include Wolfgang E. Berdel, Rolf M. Mesters, Michael Detmar, Carsten Müller‐Tidow, Torsten Keßler, Utz Krug, Christoph Schliemann, Iris Appelmann, Yong Chen and Ralf Bieker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Rüediger Liersch

31 papers receiving 925 citations

Peers

Countries citing papers authored by Rüediger Liersch

Since Specialization

Citations

This map shows the geographic impact of Rüediger Liersch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rüediger Liersch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rüediger Liersch more than expected).

Fields of papers citing papers by Rüediger Liersch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rüediger Liersch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rüediger Liersch. The network helps show where Rüediger Liersch may publish in the future.

Co-authorship network of co-authors of Rüediger Liersch

This figure shows the co-authorship network connecting the top 25 collaborators of Rüediger Liersch. A scholar is included among the top collaborators of Rüediger Liersch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rüediger Liersch. Rüediger Liersch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	409P: IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients (pts) with stage II-IIIA PD-L1 TC ≥50% NSCLC 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Rüediger Liersch, (unknown), (unknown), (unknown), Daniel Ruderman, (unknown), (unknown), (unknown), Barbara J. Gitlitz, Marcus Ballinger, Elizabeth L. Bennett, Jennifer M. Giltnane, Manoj Srivastava, (unknown)	1
2	1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC) 2024 ·Annals of Oncology ·(unknown), Martin Reck, Enriqueta Felip, (unknown), (unknown), Rüediger Liersch, Satoshi Oizumi, Hiroshi Tanaka, John Hamm, Steve McCune, (unknown), (unknown), (unknown), Silvia Novello, (unknown), (unknown), (unknown), (unknown), C.Z. Zhou	5
3	1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC) 2022 ·Immuno-Oncology Technology ·Enriqueta Felip, (unknown), Martin Reck, (unknown), (unknown), (unknown), Rüediger Liersch, M. Harada, (unknown), John Hamm, Steve McCune, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), C.Z. Zhou	13
4	2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC 2021 ·Annals of Oncology ·C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, (unknown), M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello	41
5	LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC 2021 ·Annals of Oncology ·Enriqueta Felip, Eric Vallières, C.Z. Zhou, Heather A. Wakelee, Igor Bondarenko, Hiroshi Sakai, Haruhiro Saito, (unknown), Koji Kawaguchi, Yuxin Liu, E. Levchenko, Nikolay Kislov, Martin Reck, Rüediger Liersch, Virginia McNally, Qian Zhu, Beiying Ding, Elizabeth Bennett, Barbara J. Gitlitz, Nasser K. Altorki	8
6	The miR-290-295 cluster suppresses autophagic cell death of melanoma cells 2012 ·Scientific Reports ·Yong Chen, Rüediger Liersch, Michael Detmar	51
7	Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor 2012 ·International Journal of Oncology ·Rüediger Liersch	19
8	Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator 2012 ·International Journal of Oncology ·Rüediger Liersch, Satoshi Hirakawa, Wolfgang E. Berdel, Rolf M. Mesters, Michael Detmar	35
9	POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience 2012 ·Annals of Hematology ·Gabriela B. Thoennissen, Nils H. Thoennissen, Fleur Fritz, Andreas Hilbig, Andrea Kerkhoff, Rüediger Liersch, Utz Krug, Steffen Koschmieder, Carsten Müller‐Tidow, Rolf M. Mesters, Martin Kropff, Wolfgang E. Berdel	4
10	Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B‐ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B‐cell lymphoma 2011 ·American Journal of Hematology ·Michele Pohlen, Hans Ulrich Gerth, Rüediger Liersch, Steffen Koschmieder, Rolf M. Mesters, Torsten Keßler, Iris Appelmann, Carsten Müller‐Tidow, Wolfgang E. Berdel	17
11	Tissue-factor fusion proteins induce occlusion of tumor vessels 2010 ·Thrombosis Research ·Christian Schwöppe, Torsten Keßler, Thorsten Persigehl, Rüediger Liersch, (unknown), (unknown), Janine Ring, Christoph Bremer, Walter Heindel, Rolf M. Mesters, Wolfgang E. Berdel	32
12	Angiogenesis Inhibition in Cancer Therapy 2009 ·Recent results in cancer research ·Iris Appelmann, Rüediger Liersch, Torsten Keßler, Rolf M. Mesters, Wolfgang E. Berdel	58
13	Lymphangiogenesis in Cancer: Current Perspectives 2009 ·Recent results in cancer research ·Rüediger Liersch, Christoph Biermann, Rolf M. Mesters, Wolfgang E. Berdel	13
14	Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens 2008 ·Annals of Oncology ·Lorenz Trümper, C. Zwick, Marita Ziepert, Karin Hohloch, Rudolf Schmits, Martin Mohren, Rüediger Liersch, Martin Bentz, Ullrich Graeven, U. Wruck, Martin Hoffmann, Bernd Metzner, Dirk Hasenclever, Markus Loeffler, Michael Pfreundschuh	16
15	Generation of Fusion Proteins for Selective Occlusion of Tumor Vessels 2008 ·Current Drug Discovery Technologies ·Rolf M. Mesters, Torsten Keßler, Christian Schwöppe, Rüediger Liersch, Christoph Schliemann, (unknown), Ralf Bieker, Wolfgang E. Berdel	31
16	Combined anti‐PDGFRα and PDGFRβ targeting in non‐small cell lung cancer 2008 ·International Journal of Cancer ·Niels Reinmuth, Rüediger Liersch, (unknown), Frauke Fehrmann, (unknown), Michael Bayer, (unknown), Torsten Keßler, Wolfgang E. Berdel, Michael Thomas, Rolf M. Mesters	16
17	Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia 2007 ·Leukemia ·Christoph Schliemann, Ralf Bieker, Nils H. Thoennissen, (unknown), Rüediger Liersch, Torsten Keßler, Thomas Büchner, Wolfgang E. Berdel, Rolf M. Mesters	48
18	Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia 2007 ·Leukemia Research ·Rüediger Liersch, Christoph Schliemann, Ralf Bieker, (unknown), Thomas Buechner, Wolfgang E. Berdel, Rolf M. Mesters	27
19	Induction of lymphatic endothelial cell differentiation in embryoid bodies 2005 ·Blood ·Rüediger Liersch, (unknown), Lingge Lu, Michael Detmar	50
20	Partial duplication 5q syndrome: phenotypic similarity in two sisters with identical karyotype (partial duplication 5q33 leads to 5qter and partial deficiency 8p23 leads to pter). 1977 ·PubMed ·(unknown), Rüediger Liersch	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact